Clinuvel share price opened higher after renewing CEO Agreement

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price opened more than 3% higher in morning trade after the company announced a renewed employee agreement with its CEO.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price was trading more than 3% higher in morning trade after the company announced a renewed employment agreement with its CEO.  

What did Clinuvel announce?

Clinuvel released a statement to the market this morning announcing that the company had renewed its employment agreement with CEO Dr. Philippe Wolgen for a further three years, ending 1 July 2022.  As part of the agreement, Dr. Wolgen will be on a fixed base salary of just under SGD $1.4 million (~AUD $1.5 million) and also entitled to other payments if milestones are achieved.

According to the Board of Directors, Dr. Wolgen has played a key role in restructuring the company after joining Clinuvel in 2005. In particular, the board highlighted Dr. Wolgen's contribution to increasing shareholder value by 722% over the past three years.

Dr. Wolgen was responsible for guiding the company's long-term strategy and obtaining European marketing authorisation for Clinuvel's flagship SCENESSE drug. Dr. Wolgen has also been credited for rebuilding a share registry of sophisticated and institutional investors, attracting more than $95 million in direct funding for the development and launch of SCENESSE.

How has Clinuvel performed in 2019?

Clinuvel is a global biopharmaceuticals company that develops drugs designed for the treatment of severe genetic and developmental skin disorders. The company's flagship SCENESSE drug is designed to prevent phototoxicity in patients with erythropoietic protoporphyria (EPP). SCENESSE is the first melanocortin drug to have completed a clinical trial program and obtain marketing authorisation by the European Commission. The Clinuvel share price has soared in 2019, at one point up more than 122% for the year after hitting an all-time high of $39.85.

Earlier this year Clinuvel reported strong full-year results, posting its third consecutive and record annual net profit before tax for FY19. Clinuvel saw a 21.8% increase in revenue of $31.05 million and a 40% increase in net profit before tax to a record $18.1 million for the year. Other milestones for the company included paying a maiden, unfranked dividend and joining the ASX200 index in 2019. SCENESSE continues to be the company's flagship drug, marking 3 years of continued distribution in Europe and is a key driver of Clinuvel's ability to deliver shareholder value.

Clinuvel continues to generate a solid base of earnings in Europe where the company looks set to invest in further expansion. The outlook for Clinuvel includes further growth in European distribution, obtaining FDA approval for SCENESSE to enter the US market and continued development of the company's product pipeline.  

After opening up more than 3% in morning trade, the Clinuvel share price is flat at the time of writing.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »